January 3, 2023 | News
Datar Cancer Genetics, with offices at Surrey Research Park, has announced US Food and Drug Administration (FDA) ‘Breakthrough Device Designation’ for its ‘TriNetra™-Glio’, a blood test to help in the diagnosis of brain tumours. This is the third test from the Company to have received the Breakthrough Device Designation with early-stage breast and prostate cancer detection tests becoming the first liquid biopsies to have received the award.
Worldwide, brain cancer is the 12th most lethal cancer, and each year, more than 250,000 adults die due to the disease. Diagnosis of brain tumours is resource-intensive, risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases. Presently, no blood test is available for diagnosing brain cancers, and doctors have to rely on complex surgical procedures to obtain tumour tissue for histopathological evaluation. The TriNetra™-Glio liquid biopsy is intended to detect the cells released in the blood from the brain tumour; these cells are extremely rare and hard to detect.
A prospective, blinded study by a research team at the Imperial College, London, showed the test to be highly accurate. The test requires 15 ml blood and is indicated for patients where a brain biopsy, although necessary, cannot be performed or has been unsuccessful.
Dr. Kevin O’Neill, Consultant Neurosurgeon, Chairman of the Brain Tumour Research Campaign and Principal Investigator for the Brain Tumour Research Charity’s Centre of Excellence working at the Imperial College, London, who led the blinded study to evaluate the test said:
“In my opinion, a non-invasive blood test that detects circulating tumour cells (CTCs) would help to address many of the problems associated with complex brain tumour diagnosis. As a surgeon working on other technologies to define the tumour and functional boundary during surgery to a molecular level of accuracy and to shorten the diagnostic pathway that would inform surgeons, I find this technology of significant interest. In particular, the intended indication to provide a liquid biopsy diagnosis from a simple blood test where tumours are deemed inoperable or inaccessible will truly address an unmet clinical need. I have found this test to be highly sensitive and specific. This breakthrough technology has true diagnostic utility by detecting cells rather than picking up molecular indicators of disease, which until now liquid biopsies have been based upon.”
Dr. Vineet Datta, Executive Director of the Company said:
“The breakthrough designation is a recognition of the potential benefits of TriNetra™-Glio in the clinical setting. The test can help individuals where a brain biopsy or surgical resection of the tumour is not possible due to the location of the tumour or other constraints. With our proprietary CTC-enrichment and detection technology, a diagnosis of inaccessible tumors will become possible through a risk-free and patient-friendly blood test.”